StockData

Immutep vs Zentalis Pharmaceuticals

IMMP and ZNTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IMMP and ZNTL compare

Immutep scores higher on the StockData Score (8 against 6 for Zentalis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIMMPZNTL
Size and price
Market cap–$107M
Share price$3.26$1.49
Change, 1 year−91.2%12.0%
Change, 5 years−95.2%−98.0%
Beta (5Y)4.325.80
Employees46106
StockData Score
Total score8 (better)6
Valuation score01 (better)
Growth score2 (better)0
Performance score1 (better)0
Health score55
Dividend score00
Valuation
P/B–0.7×
FCF yield–−120%
Growth
Revenue growth (TTM)134%–
Revenue growth, 5Y average43.5%–
Profitability
Net margin−328%–
FCF margin−230%–
Return on equity−77.3%−66.7% (better)
Financial health
Debt / equity0.000.00
Current ratio5.69 (better)4.82
Altman Z-score–−8.91
Piotroski F-score2 (better)1
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–66.1%
Held by insiders0.89%58.0%
Insider net buying, 12 months–$12.8M
Short interest, % of float–16.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.